Necrotising cutaneous lesions as a side effect of glatiramer acetate (Q83988710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Necrotising cutaneous lesions as a side effect of glatiramer acetate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Isabel Bosca

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Maria Bosca

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Antonio Belenguer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Monserrat Evole

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Miguel Hernandez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Bonaventura Casanova

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Francisco Coret

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

13 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1370-1371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16773267%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-006-0233-9

29 January 2020

exact match

0 references

cites work

Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a

1 reference

12 December 2020

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

1 reference

12 December 2020

[Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)]

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

1 reference

12 December 2020

Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis

1 reference

12 December 2020

Animal experiment studies of embolia cutis medicamentosa

1 reference

12 December 2020

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020